Introduction. After premenopausal risk-reducing salpingo-oophorectomy (RRSO) to prevent ovarian cancer, the non-cancer-related morbidity and mortality may be increased if sex hormones are not replaced. Several guidelines recommend systemic hormone replacement therapy (HRT) to these women until the expected age of menopause. We aimed to study the use of HRT after RRSO. Material and methods. Participants were 324 women after RRSO and 11 160 postmenopausal controls. A subsample of 950 controls had undergone bilateral salpingo-oophorectomy (BSO). All participants completed the same questionnaire regarding HRT use. We compared HRT use in the RRSO group with the BSO controls using logistic regression. Results. Among the women aged ≤52 years without a history of breast cancer, 51.7% of the RRSO group and 48.7% of the BSO controls reported current use of systemic HRT (odds ratio 1.13, 95% confidence interval 0.72-1.76). Among the HRT users, systemic estrogen was used by 35.1% and 58.7% in the RRSO and BSO control groups, respectively (p = 0.001). Among the women aged >52 years, 16.8% of the RRSO group and 38.4% of the BSO controls (p < 0.001) used systemic HRT. Conclusions. Among the RRSO women and BSO controls ≤52 years old without a history of breast cancer, relatively few were current users. If there are no contraindications, these women would benefit from systemic HRT. Additionally, almost 40% of the BSO controls >52 years used systemic HRT. Doctors should be aware of this practice and prescribe systemic HRT when indicated.
Introduction
Breast cancer (BRCA) gene mutations cause 8-13% of the cases of epithelial ovarian cancer (1) . In BRCA mutation carriers, the cumulative risk of epithelial ovarian cancer at age 75 years is 15-60% (2, 3) . Surgical removal of the ovaries and fallopian tubes, risk-reducing salpingo-oophorectomy (RRSO), is the most effective preventive method to avoid ovarian cancer in women at increased risk. The procedure reduces ovarian cancer risk by approximately 80% (4) and is recommended between the ages of 35 and 45 (5) . RRSO leads to immediate menopause, which may result in several unwanted health effects. After premenopausal RRSO, women have reported more menopausal symptoms (6) (7) (8) , reduced sexual functioning (7, 9) ; a high rate of bone loss has also been noted (6) . These unwanted effects are reduced by systemic hormone replacement therapy (HRT) (6) (7) (8) (9) . Nevertheless, most evidence of unwanted late effects is based on follow up after bilateral salpingo-oophorectomy (BSO) for purposes other than riskreduction. BSO at young ages and without HRT increases cardiovascular mortality (10) and overall mortality (11) . Rocca et al. found that premenopausal uni-or bilateral oophorectomy increased the risk of dementia and cognitive impairment in women without HRT (12) .
Norwegian guidelines (13) are in accordance with Australasian (14) , North American (15) , and UK guidelines (16) in recommending systemic HRT from the RRSO procedure until the age of natural menopause, if there is no history of breast cancer.
Based on our clinical experience in gynecologic oncology, it is difficult to find good HRT regimens for women after RRSO. The women are often reluctant to have HRT because they, and often also their doctor, fear the risk of breast cancer (6) . Nevertheless, it is likely that women after premenopausal RRSO will benefit from HRT. Our primary aim was to determine the proportion of current HRT users among the young women (≤52 years) in the RRSO group without a history of breast cancer, compared with BSO controls. The secondary aims were: (1) to determine the use of HRT among women aged ≥52 years in the RRSO group compared with BSO controls and (2) to describe the use of HRT among women with a history of breast cancer in the RRSO group compared with controls.
Material and methods

Risk-reducing salpingo-oophorectomy
Participants were recruited through surgical records from three university hospitals in Norway. We identified 503 women at increased risk of hereditary breast and ovarian cancer who underwent RRSO in the period 1978-2005. The women were invited to participate by a mailed questionnaire through 2006 and 2007, and nonresponders were sent a reminder after three weeks. Except for age at survey and age at RRSO, we had no information about the nonresponders.
Controls
The Norwegian Women and Cancer study (NOWAC) started enrollment in 1991, and was conducted to determine associations between lifestyle and cancer risk (17) . In the present study, the control groups were based on a sample of 30 000 women from the NOWAC cohort. The women were invited to participate by mailed questionnaires through 2005 and 2006. For comparison with the RRSO group, we used controls who had undergone BSO (BSO controls) and a control group that included all postmenopausal women (total group of controls). We did not know the indication for BSO among the controls. The inclusion of the participants is shown in Figure 1 .
Except for date of birth, date of survey, and age at RRSO, all data were self-reported in the RRSO group. Education was dichotomized into low education defined as ≤12 completed school years and high education meaning >12 years. Women in paired relations were married, cohabiting, or widowed. History of breast cancer in the RRSO group was self-reported at the time of inclusion. The NOWAC cohort was linked to the Norwegian Cancer Register to register breast cancer incidences in the controls. The NOWAC cohort was enrolled between 24 February 2005 and 18 April 2006. Women who were diagnosed with breast cancer between the enrollment dates were excluded from the analyses concerning history of breast cancer. In the NOWAC cohort, the women were defined as postmenopausal if they answered that they no longer had periods, and/or gave a reason for cessation of periods, and/or gave the age when the periods stopped. If the women used HRT, had a hormonal intrauterine device, had undergone hysterectomy, or did not know their own menopausal status, they were classified as postmenopausal if aged >52 years. If they were aged ≤52 years, they were classified as uncertain menopausal status (18) .
In both the RRSO and NOWAC groups, participants reported current and former use and duration of HRT using a validated questionnaire (18) . The preparations were categorized into systemic estrogen, progestogen, combination preparations (estrogen + progestogen), tibolone, local
Key Message
After risk-reducing salpingo-oophorectomy, young women without breast cancer are recommended systemic hormone therapy. We found that only half of the eligible women used hormones, which implies that many of these women unnecessarily experience adverse effects. preparations (vaginal application), both systemic and local preparations, contraceptive pills, and unknown preparations. Use of systemic HRT was classified as current, former or never.
Statistical analyses
Findings were described by medians and ranges for continuous variables, and by proportions for categorical variables. Differences between groups were assessed by the Mann-Whitney U-test for continuous variables due to skewed distributions, and by chi-square tests for categorical variables. We used logistic regression to control for possible confounders (age and history of breast cancer). We performed multivariable logistic regression using systemic hormones as the dependent variable to study predictors of hormone use. The contribution made by each covariate was expressed as odds ratios (OR) with 95% confidence intervals (CI). The level of significance was set at p < 0.05, and all tests were two-tailed. The statistical Package for the Social Sciences (SPSS) version 18.0 (SPSS Inc., Chicago, IL, USA) was used.
The study was approved by the Regional Committee for Medical and Health Research Ethics South East Norway in September 2012 (REC number 2012/1165).
Results
Study samples
The women in the RRSO group were younger than the BSO controls (median age 53.5 and 56 years, respectively, p = 0.001). No significant difference in education or marital status was found between the RRSO group and the BSO controls (Table 1) .
HRT use in women ≤52 years without a history of breast cancer in the RRSO group and BSO controls In this subgroup, 51.7% of the RRSO group and 48.7% of the BSO controls used systemic HRT (OR 1.13, 95% CI 0.72-1.76) ( Table 2 ). Among the current HRT users, significantly fewer women used estrogens in the RRSO group compared with the BSO controls (35.1 vs. 58.7%, p = 0.001). There were no significant differences in the use of combination preparations (estrogen + progestogen) or tibolone between the RRSO group and the BSO controls ( Figure 2 ).
HRT use among women >52 years in the RRSO group compared with the BSO controls Among the RRSO women >52 years, 52 (29.1%) reported current use of either systemic or local HRT compared with 318 (45.0%) of the BSO controls (OR 0.63, 95% CI 0.44-0.92, adjusted for breast cancer). Thirty (16.8%) women in the RRSO group reported current use of systemic HRT compared with 271 (38.4%) of the BSO controls (OR 0.44, 95% CI 0.29-0.68, adjusted for breast cancer) (Table 3) . Fewer RRSO women used estrogen and more RRSO women used tibolone compared with the BSO controls ( Figure 3 ).
Predictors of systemic HRT use
Current use of systemic HRT was negatively associated with age (OR 0.93, p < 0.001) and history of breast cancer (OR 0.109, p < 0.001). None of the variables "RRSO vs. BSO controls," education or civil status was significantly associated with use of systemic HRT (Table 4) . Figure 1 . Inclusion of the participants. BSO, bilateral salpingo-oophorectomy; NOWAC, the Norwegian Women and Cancer study; RRSO, riskreducing salpingo-oophorectomy.
HRT use among women with a history of breast cancer
Of the 80 RRSO women with a breast cancer diagnosis, 14 (17.5%) reported HRT use, which is comparable to the BSO controls with breast cancer (OR 1.22, 95% CI 0.364-4.08, adjusted for age) (Table S1 ). In both the RRSO and BSO control groups, local preparations were most frequently reported (Table S2 ).
Discussion
Our main finding was that among the women ≤52 years and with no history of breast cancer, only 51.7% of the RRSO group and 48.7% of the BSO controls used HRT. Current use of systemic HRT in young women after RRSO without a history of breast cancer has ranged from 44 to 71% in previous studies (7, 8, 19) . The most recent of these studies was conducted by Tucker et al. in 2015 Total group of controls, control women from the Norwegian general population who were postmenopausal for any reason. BSO controls, control women from the Norwegian general population who had undergone BSO. BSO, bilateral salpingo-oophorectomy; RRSO, risk-reducing salpingo-oophorectomy. (20) and the HRT after Breast CancerIs it Safe? (HABITS) study (21) . Both trials were stopped early because of higher incidence of breast cancer in the HRT groups compared with the placebo/control groups. However, in the WHI study, the participants were women aged 50-79 years from the general population, and the results may not be applicable to young women after RRSO. Moreover, although The Stockholm Study had a similar design to the HABITS study, it did not report an increased risk of breast cancer recurrence in hormone users (22) 78 women (72%) who had never used HRT after RRSO explained the nonuse by fear of breast cancer (6) . However, there was no information on how the reasons for nonuse were reported, or on the proportion of women with a history of breast cancer within this group. There are few studies on breast cancer risk and HRT after RRSO. Rebbeck et al. conducted a prospective study and found that short-term HRT use did not negate the effect of RRSO on the reduction in breast cancer risk (23) . However, the mean follow up was only 3.5 years, which makes it difficult to extrapolate the findings to long-term use after RRSO. In comparison, the WHI study had 8500 participants in the estrogen + progestogen arm and was stopped after 5.2 years because the breast cancer risk was increased. Although the participants in the study by Rebbeck et al. (23) carried a higher risk for breast cancer, it may be argued that the study (n = 462) was underpowered to show an increase in breast cancer. Studies with longer follow up from this cohort are awaited. Eisen et al. performed a matched case-control study including 472 BRCA carriers and found no association between HRT and breast cancer (24) . Based on the existing literature, women after RRSO should be advised to use HRT if they are below the expected menopausal age and have no history of breast cancer. These conclusions are in accordance with earlier published recommendations (25) . However, there are no randomized controlled trials that address HRT after RRSO, and observational studies provide few data on BRCA2 carriers. The present recommendations are therefore based on limited data, and future studies are needed.
Howell et al. (26) summarized the use of HRT combination preparations (estrogen + progestogen) vs. estrogen alone and the risk of breast cancer in a 2011 review. They concluded that there are paradoxical effects, as there is evidence that HRT may both stimulate and inhibit breast cancers. While combination preparations increased the risk of breast cancer, estrogen alone did not, and in some observational studies in young women, estrogen alone was associated with a reduced risk of breast cancer. The current literature therefore suggests that there are different effects on breast cancer risk depending on the age of the woman, genetic predisposition, and the HRT preparation that is prescribed.
Among the young current HRT users without breast cancer in the present study, estrogen only was used by 26 women (35.1%) in the RRSO group and by 71 (58.7%) of the BSO controls. This difference may reflect that a higher proportion of the BSO controls had undergone hysterectomy; however, we did not have access to hysterectomy data in the study groups. A difference in the proportion of women with a hysterectomy may also explain why more women in the RRSO group used combination preparations (24.3%) and tibolone (20.3%) compared with the BSO controls (14.9 and 13.2%, respectively). Shu et al. recently reported an increased risk of serous and serous-like uterine cancer in BRCA1 carriers after RRSO without hysterectomy, although their numbers were small (27) . If these findings are confirmed in future studies, hysterectomy should be considered in guidelines on risk-reducing gynecologic surgery to prevent BRCA associated pelvic cancer. The large proportion of tibolone prescriptions in the RRSO group was probably due to the proposed positive effect on sexual functioning compared with combination preparations (28) .
In the present study, having a history of breast cancer and increasing age were associated with being a nonuser. These analyses indicate that women were less likely to be (20) . If HRT increases the risk of breast cancer in postmenopausal women from the general population, it can be assumed that the risk will be even higher for women with BRCA mutations at postmenopausal ages. When to discontinue HRT is therefore an important issue in future trials and guidelines. In 2012, Finch et al. reported a comprehensive review that included morbidity following RRSO at young age and considerations about the safety of HRT use (29) . They provided an overview of recommendations on HRT use based on history of breast cancer, type of BRCA mutation, and mastectomy status. Based on available data, they concluded that we still do not know whether it is safe for women to use estrogen compared with combination preparations. Studies since then have emphasized that estrogen alone probably does not increase breast cancer risk, and such therapy should therefore be considered in eligible women (30) . Because estrogen alone increases the risk of endometrial cancer, it should not be given to women with an intact uterus.
In addition to breast cancer, contraindications to systemic HRT include estrogen-sensitive tumors, undiagnosed vaginal bleeding or endometrial hyperplasia, venous thromboembolism, cardiovascular disease, severe hepatic disease, and porphyria cutanea tarda (13, 16) . Among the 116 RRSO women ≤52 years and without a history of breast cancer in the present study, one woman had angina pectoris, two women did not answer the questions concerning cardiovascular and cerebrovascular diseases, and 113 women reported no cardiovascular or cerebrovascular disease (data not shown). The questionnaires did not cover the remaining contraindications to systemic HRT use. However, the annual risk of endometrial malignancy for women between 35 and 55 years is very low (31, 32) and chronic liver disease and porphyria cutanea tarda are rare conditions (33, 34) . Hence, among the RRSO and BSO control women ≤52 years and without a history of breast cancer the prevalence of contraindications to HRT use is probably very low. Nevertheless, we cannot disregard that some of these women had conditions considered to contraindicate systemic HRT use.
The present study has limitations. First, the RRSO group was based on surgical records from three Norwegian university hospitals and may not be representative of all Norwegian BRCA carriers. Secondly, the study design does not enable us to explain why large subsets of the RRSO and control groups were nonusers. Thirdly, HRT use is self-reported, which may lead to misclassification of users. However, other methods to assess HRT use would not necessarily be more robust. Fourthly, we were not able to determine the use of testosterone therapy because the HRT questionnaire did not include questions concerning testosterone preparations. The time since the data were collected may be considered a weakness, because trends of HRT use may change over time. However, we have no reason to believe that doctors prescribe HRT to women after RRSO or BSO more often now than in the study period (35) . Finally, the data on history of breast cancer and removal of the ovaries was collected differently in the RRSO and control groups. Breast cancer was self-reported in the RRSO group and based on the Cancer Registry of Norway in the control groups. However, since the sensitivity and specificity or self-reported breast cancer is reported to be high (36), we believe that the accuracy of self-reported history of breast cancer in the RRSO group approaches the accuracy that was obtained in the control group. Data on the removal of the ovaries in the RRSO group was taken from medical journals and were self-reported by the controls. Selfreported BSO had only 64% sensitivity in a validation study including 1010 US women (37) , which may lead to an underestimation of the number of BSO controls. However, the positive predictive value of self-reported BSO in the same study was 100% (37) . We therefore believe that literally all the women who self-reported RRSO and BSO actually had had both their ovaries removed.
The strengths of the study were the large groups of both RRSO women and controls. We believe that the control groups were representative of the Norwegian population (17) . Another strength was that the RRSO and the control groups answered the same HRT questionnaire in the same time period (2005-2007) ; hence, all the participants were likely exposed to comparable HRT trends when reporting on HRT.
Conclusions
The present findings of approximately 50% HRT users among the young women without a history of breast cancer imply that the guidelines of HRT use after RRSO might not have been followed. There are contraindications to systemic HRT other than breast cancer, but these conditions are rare among women at premenopausal age.
The HRT non-users may have more postmenopausal symptoms than necessary and may be at risk of diseases associated with the estrogen deprivation. Doctors should be aware of these findings when counseling BRCA carriers before RRSO, and in the follow up to the preventive surgery.
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